Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES（2023）
Key words
squamous cell lung cancer,lung cancer,nivolumab,ipilimumab,checkpoint inhibition therapy,abemaciclib,TMB-high
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined